MC:EURONEXT PARISLVMH Moet Hennessy Louis Vuitton SE Analysis
Data as of 2026-05-19 - not real-time
$63.16
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Moelis & Company is trading at $63.16, which sits below its 20‑day SMA of $65.27 and the 200‑day SMA of $67.01, indicating short‑term weakness, while remaining just above the 50‑day SMA of $61.08. Technical signals are mixed: the MACD histogram is negative and the MACD line trails its signal, the RSI sits at 46 (neutral), and volume has been trending down, all pointing to a cautious near‑term outlook. The latest earnings missed expectations, with adjusted EPS of $0.50 versus the consensus $0.59 and a 21.9% decline in net profit YoY, which pressured the stock despite a modest 4.3% revenue increase. Fundamentally, the firm remains strong with a gross margin of 92.3%, operating margin of 12.7%, and an impressive ROE of 41.8%, but its forward P/E of 15.98 suggests a more reasonable valuation than the current trailing P/E of 22.7, which is above the industry average of 16.6. The DCF‑derived fair value of $66.48 provides roughly a 12% upside, aligning with analyst median targets around $70, while the dividend yield of 4.07% is attractive but the payout ratio of 93.5% raises sustainability concerns. Overall, the market is in an "Extreme Greed" phase (Fear & Greed Index 89.45), but high beta (≈1.6) and 30‑day volatility of 34% underscore significant risk as the stock navigates near its support at $61.85 and faces resistance near $71.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Q1 earnings miss and lower EPS than consensus
- Bearish MACD and decreasing volume
- High dividend yield but near‑full payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value indicates ~12% upside
- Strong ROE and high gross margins
- Forward P/E compression toward industry norms
Long Term
> 3 yearsNeutral
Model confidence: 8/10
Key Factors
- Sustainable advisory franchise with global reach
- Consistently high profitability metrics
- Dividend attractiveness tempered by payout sustainability concerns
Key Metrics & Analysis
Financial Health
Revenue Growth4.30%
Profit Margin14.46%
P/E Ratio22.7
ROE41.77%
ROA19.89%
Debt/Equity42.94
P/B Ratio9.6
Op. Cash Flow$463.0M
Industry P/E16.6
Technical Analysis
TrendNeutral
RSI46.1
Support$61.85
Resistance$70.97
MA 20$65.27
MA 50$61.08
MA 200$67.01
MACDBearish
VolumeDecreasing
Fear & Greed Index89.45
Valuation
Fair Value$66.48
Target Price$71.00
Upside/Downside12.42%
GradeUndervalued
TypeBlend
Dividend Yield4.07%
Risk Assessment
Beta1.61
Volatility34.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.